Alnylam Pharmaceuticals, Inc.
0HD2.L
London Stock Exchange321.96
USD
+8.12
- -
Alnylam Pharmaceuticals, Inc.
0HD2.L
(London Stock Exchange)
Recent
price
321.96
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY; FSE: 0HD2) develops and commercializes RNA interference (RNAi) therapeutics for genetically defined diseases, including rare and prevalent conditions such as transthyretin amyloidosis (ATTR), acute hepatic porphyrias, primary hyperoxaluria type 1, hemophilia, and cardiometabolic disorders; core products comprise AMVUTTRA (vutrisiran) for polyneuropathy of hereditary ATTR amyloidosis and ATTR cardiomyopathy, ONPATTRO (patisiran) for hereditary ATTR amyloidosis with polyneuropathy, GIVLAARI (givosiran) for acute hepatic porphyrias, and OXLUMO (lumasiran) for primary hyperoxaluria type 1, with partnered programs including Novartis' Leqvio (inclisiran) for hypercholesterolemia and Sanofi's fitusiran (Qfitlia) for hemophilia A and B. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company operates globally with facilities and subsidiaries in the US (including manufacturing in Norton, Massachusetts), UK (Maidenhead), Switzerland (Zug), Japan (Tokyo), Italy (Milan), and maintains a robust pipeline of over 25 investigational RNAi programs targeting ATTR cardiomyopathy (vutrisiran expansion), obesity, CNS disorders, beta thalassemia, hypertension, liver infections, Alzheimer's (mivelsiran), and additional Alnylam-led initiatives, advancing toward its Alnylam P 5x25 strategy for sustainable innovation across rare and common diseases. Recent developments include preliminary full-year 2024 net product revenues of $1.646 billion (33% growth), raised 2025 revenue guidance to $2.95-3.05 billion driven by AMVUTTRA sales and ATTR-CM opportunity, potential FDA approval of fitusiran by March 2025, a $310 million royalty sale on AMVUTTRA to Royalty Pharma from Blackstone in November 2025, international expansions for AMVUTTRA in Germany, Japan, Brazil, and the EU, positive HELIOS-B Phase 3 data showing amyloid regression and kidney function preservation, a proposed $500 million convertible senior notes offering in September 2025, and Board of Directors changes in December 2025 with departures of Mike Bonney and Carolyn Bertozzi and appointment of Stuart Arbuckle.